查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496004

全球生物製品市場：2024-2029 年預測

Global Biologics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 121 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

生物製品市場預計將從 2022 年的 4,021.82 億美元成長到 2029 年的 7,611.39 億美元，複合年成長率為 9.54%。

市場的長期前景取決於市場參與企業不斷增加的財務投資、癌症和自體免疫疾病等慢性疾病的出現以及對先進技術治療方法日益成長的熱情。據世界衛生組織 (WHO) 稱，癌症是全球最常見的死亡原因，預計到 2022 年將有 970 萬人受到該疾病的影響。肥胖、水果和蔬菜攝取量低、缺乏體力活動以及菸草和酒精消費的增加預計將在未來幾年增加癌症病例。

全球人口老化趨勢也將產生對生物製藥的需求。研究和開發的資本投入也是預期對市場成長產生正面影響的因素之一。然而，單株抗體、重組 DNA 技術、治療性蛋白質和疫苗等新型治療方案的興起正在推動生物技術和製藥公司生產生物製藥。此外，現在的公司非常關注研發和製造設施。

  • 慢性病的流行、對學名藥的需求增加以及疫苗產量的增加

在糖尿病、氣喘、癌症和自體免疫疾病等慢性疾病增加的強力支持下，該市場正在不斷成長。大量的慢性病意味著對生物藥物的需求增加。同時，對抗登革熱、瘧疾和屈公病的疫苗接種激增正在推動生物製品市場的成長。此外，人口成長正在減少印度、中國和美國等全球主要參與者對學名藥的需求。

許多國家正在共同開發可用於治療各種疾病的疫苗和醫療設備，例如犬藏紅花。此外，隨著主要企業增加對綜合設施的持續投資，市場成長預計將進一步增加。例如，2024年1月，艾伯維將投資2.23億美元擴大新加坡工廠，以擴大其生物製劑生產設施。這項重大投資將重點用於將生物製品原料產能提高 24,000 公升，並創造 100 多個新工作機會。除了生產現有產品外，還將為免疫學和腫瘤學領域的下一代產品的生產做出貢獻。

  • 生物製品市場按應用細分為腫瘤學、神經學、循環系統、血液學、自體免疫疾病、感染疾病等。

全球癌症死亡率的上升和癌症研發活動是顯示該市場未來擴張潛力的兩個因素。此外，根據癌症的類型，生物製藥療法比傳統的放射線治療或化療具有更少的副作用，這也促進了癌症領域生物製藥市場的開拓趨勢。此外，治療多種癌症的新生物療法的出現將為多種癌症提供治療選擇。因此，這將促進生物製藥市場腫瘤領域的開拓。

例如，美國癌症協會發表的一篇論文估計，2023年1月，美國將新增1,958,310例癌症病例，609,820例癌症相關死亡病例。隨著世界各地新癌症患者和癌症死亡人數迅速增加，全球腫瘤學活動可能活性化。除此之外，世界各地還有許多生物療法用於檢測和治療癌症，包括免疫療法、基因療法、過繼性細胞移植和化療。例如，免疫療法等生物療法可用於治療多種癌症，包括最常見的肺癌、乳癌和皮膚癌。

此外，免疫療法並沒有使用有毒化學物質來消除癌細胞和非癌細胞，這就是化療的概念。在約翰霍普金斯大學的第二個案例研究中，默克細胞癌（一種侵襲性皮膚癌）透過免疫療法得到了更有效的治療。結果，存活率提高了。此外，2022年2月，CRI發布了針對免疫PD1/PDL1查核點的臨床藥物開發的全球現況。

例如，2023年，Astra Zeneca在其臨床試驗增刊中發表了報導，其中重點介紹了目前正在試驗中效果最好的一些藥物。 Tagrisso（醫學術語： Osimertinib）是一種高效能抗癌藥物，作為輔助治療形式用於治療肺癌。該藥物被歸類為 EGFR 抑制劑，其特性使其有別於其他藥物。憑藉其高度選擇性和不可逆的作用機制，Tagrisso 精確靶向具有 EGFR 突變的癌細胞，並與其建立持續的聯繫，最終抑制其增殖。這些重大發展和腫瘤生物製藥的好處將導致生物製藥在全球市場的市場佔有率。

市場挑戰

  • 新治療方法的市場開拓成本不斷上升，限制了生物製劑市場的成長。

由於複雜的開發和製造流程、漫長的臨床試驗以及政府當局的嚴格監管，開發和製造生物製藥的成本高昂。這些因素會影響患者的就診並導致醫療保健投資增加。

  • 生物製劑的壽命短也阻礙了生物製劑市場的成長。

各種生物製品在環境中的持久性比傳統藥物低，因此需要安全儲存並防止作為廢棄物處置。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球生物製品市場：依產品類型

  • 介紹
  • 單株抗體
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 疫苗
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 重組蛋白
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 基因治療
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 基於細胞的生物製劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球生物製品市場：依應用分類

  • 介紹
  • 腫瘤學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 神經病學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 心臟病學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 血液學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 自體免疫疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 感染疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章 全球生物製品市場：依地區分類

  • 介紹
  • 北美洲
    • 依產品類型
    • 按用途
    • 按國家/地區
  • 南美洲
    • 依產品類型
    • 按用途
    • 按國家/地區
  • 歐洲
    • 依產品類型
    • 按用途
    • 按國家/地區
  • 中東/非洲
    • 依產品類型
    • 按用途
    • 按國家/地區
  • 亞太地區
    • 依產品類型
    • 按用途
    • 按國家/地區

第8章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第9章 公司簡介

  • Hoffmann-La Roche AG
  • Amgen Inc.
  • AbbVie Inc.
  • Novo Nordisk A/S
  • Johnson & Johnson
  • Takeda Pharmaceutical Company
  • Alexion Pharmaceuticals
  • Samsung Biologics
  • UCB SA
  • Merck & Co. Inc
  • Eli Lilly and Company
  • Sanofi SA
簡介目錄
Product Code: KSI061611837

The global biologics market is projected to grow at a CAGR of 9.54% to reach US$761.139 billion by 2029, from US$402.182 billion in 2022.

The long-term outlook of the market is determined by the increasing financial investments of the dominant market participants, the advent of chronic diseases like cancer and autoimmune illnesses, and the increasing enthusiasm for technologically advanced therapies. According to the World Health Organization, the most commonly detected cause of death worldwide is cancer and its consequences were recorded as nearly 9.7 million in 2022. Expanding tobacco and alcohol intake along with obesity, low levels of fruit and vegetable intake, and the lack of physical exercise are expected to increase the cases of cancer in the coming years.

The worldwide trend of an aged population is also supposed to create the need for biological products. Besides, capital injections in research and development are among the factors expected to have a positive influence on market growth. However, a growing number of novel treatment options like monoclonal antibodies, recombinant-DNA technology, therapeutic proteins, and vaccines driving the biotechnological and pharmaceutical companies towards the production of biologics. Also, companies have recently given a lot of attention to research and development or manufacturing facilities.

  • Rising prevalence of chronic disease & Growing demand for generic drugs along with an increase in the production of vaccines

The market is growing with strong support from the rising of chronic diseases such as diabetes, asthma, cancer, auto-immune disease, and so on. Huge numbers of chronic diseases mean increasing demand for biological medicines. On the other side, surging vaccination production for the entire globe to fight dengue, malaria, and chikungunya is propelling the growth of the global biologics market. In addition, the enlarged population also lowers the demand for generic drugs in major global players like India, China, and the US.

Many countries work together for a vaccine and medical devices that could be utilized in the cure of various diseases like caner. Further, greater investments in the ongoing integrated facilities for the key players will add to the market growth. For instance, in January 2024 AbbVie is expanding its biologics manufacturing facilities via a substantial $223 million investment in expansion of its Singapore plant. This meaningful investment will concentrate on the increase of the capacity by 24 thousand liters of biologics drug materials and the creation of more than 100 new job positions. Apart from the production of the current items, they will also be instrumental in the production of next-generation products in the fields of immunology and oncology.

  • Based on application, the global biologics market is segmented into oncology, neurology, cardiology, hematology, autoimmune diseases, infectious diseases, and others.

The worldwide rise in cancer mortality rates and cancer research and development activities are two factors that show a likelihood for the future increase of this market. Further, biologics treatment demonstrates fewer side effects than conventional radiotherapy/chemotherapy for some cancer types which also plays a part in the development trend of the biologics market in the oncology sector. Moreover, as new biologic therapeutics become available for treating more than one type of cancer, it will provide treatment options for multiple types of cancer. Therefore, this will drive the oncology segment of the biologic drugs market's development.

For instance, according to the American Cancer Society published article, in January 2023 it is evaluated that in the year 2023, there will be 1,958, 310 new cases of cancer and 609, 820 cancer-associated fatalities in the United States region. These incredible numbers surge in new cases and people who die of cancers worldwide will possibly lead to the global rise of activities in oncology. In addition to these, there are many other biological treatments including immunotherapy, gene therapy, adoptive cell transfer, bio-chemotherapy, and so on to discover and treat cancers around the globe. For example, such biological treatment as immunotherapy can be used for the treatment of many different cancers including lung, breast, and skin cancer, the most common types.

Furthermore, immunotherapy does not annihilate both cancer and non-cancer cells by toxic chemicals, which is the concept of chemotherapy. The second case study according to Johns Hopkins University, Merkel cell carcinoma - an aggressive type of skin cancer - was treated more effectively with immunotherapy. It resulted in better survival rates. Also, CRI came out in public in February 2022 with the global landscape of clinical drug development targeting immune PD1/PDL1 checkpoints.

For instance, in 2023 AstraZeneca published an article on clinical trials appendix in which there are some medications that are under trial and showing the best results as the output Tagrisso, or osimertinib in medical terminology, is a very powerful anticancer drug for lung cancer treatment, as a form of adjuvant therapy. This drug is classified as an EGFR inhibitor which is defined by its having a property that is distinguishable from other drugs. By having a highly selective and irreversible mechanism of action Tagrisso aims precisely at the cancer cells with EGFR mutations and establishes a continuous connection with them, thus, ultimately, inhibiting their proliferation. These key developments, as well as the benefits contributed by biologics in oncology, will bring the market share of biologics in the oncology segment to the global market.

Market Challenges

  • Surge in the cost of development of new treatment options curbs the global biologics market growth.

The creation and production of biologics is costly due to the intricate process in the development and manufacturing process, prolonged clinical trials, and strict regulations by government authorities. These factors influence the patient's access and incur more healthcare investments.

  • The short life span of biologics hinders the global biologics market growth.

The various biologics don't sustain more in the environment as compared to traditional or conventional drugs these biologics need to be taken care of in the inventory by preserving safely by preventing the material from being disposed of as waste.

Key Developments

  • In March 2023: Sanofi a renowned pharmaceuticals and healthcare company has initiated its first biological drug called Dupixent which is specifically designed for the treatment of COPD. This drug inhibits good results during the various primary trials which help in the management process of COPD.

Market Segmentation

BY PRODUCT TYPE

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Gene Therapy
  • Cellular-based Biologics
  • Others

BY APPLICATION

  • Oncology
  • Neurology
  • Cardiology
  • Hematology
  • Autoimmune Diseases
  • Infectious Diseases
  • Others

BY GEOGRAPHY

  • North America
  • U.S
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Asia Pacific
  • China
  • Japan
  • India
  • Indonesia
  • South Korea
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BIOLOGICS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Monoclonal Antibodies
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Vaccines
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Recombinant Proteins
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Gene Therapy
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Cellular-based Biologics
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness
  • 5.7. Others
    • 5.7.1. Market Opportunities and Trends
    • 5.7.2. Growth Prospects
    • 5.7.3. Geographic Lucrativeness

6. GLOBAL BIOLOGICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Oncology
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Neurology
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Cardiology
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Hematology
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Autoimmune Diseases
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness
  • 6.7. Infectious Diseases
    • 6.7.1. Market Opportunities and Trends
    • 6.7.2. Growth Prospects
    • 6.7.3. Geographic Lucrativeness
  • 6.8. Others
    • 6.8.1. Market Opportunities and Trends
    • 6.8.2. Growth Prospects
    • 6.8.3. Geographic Lucrativeness

7. GLOBAL BIOLOGICS MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By Country
      • 7.2.3.1. U.S.
        • 7.2.3.1.1. Market Opportunities and Trends
        • 7.2.3.1.2. Growth Prospects
      • 7.2.3.2. Canada
        • 7.2.3.2.1. Market Opportunities and Trends
        • 7.2.3.2.2. Growth Prospects
      • 7.2.3.3. Mexico
        • 7.2.3.3.1. Market Opportunities and Trends
        • 7.2.3.3.2. Growth Prospects
  • 7.3. South America
    • 7.3.1. By Product Type
    • 7.3.2. By Application
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
        • 7.3.3.1.1. Market Opportunities and Trends
        • 7.3.3.1.2. Growth Prospects
      • 7.3.3.2. Argentina
        • 7.3.3.2.1. Market Opportunities and Trends
        • 7.3.3.2.2. Growth Prospects
      • 7.3.3.3. Others
        • 7.3.3.3.1. Market Opportunities and Trends
        • 7.3.3.3.2. Growth Prospects
  • 7.4. Europe
    • 7.4.1. By Product Type
    • 7.4.2. By Application
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
        • 7.4.3.1.1. Market Opportunities and Trends
        • 7.4.3.1.2. Growth Prospects
      • 7.4.3.2. Germany
        • 7.4.3.2.1. Market Opportunities and Trends
        • 7.4.3.2.2. Growth Prospects
      • 7.4.3.3. France
        • 7.4.3.3.1. Market Opportunities and Trends
        • 7.4.3.3.2. Growth Prospects
      • 7.4.3.4. Italy
        • 7.4.3.4.1. Market Opportunities and Trends
        • 7.4.3.4.2. Growth Prospects
      • 7.4.3.5. Spain
        • 7.4.3.5.1. Market Opportunities and Trends
        • 7.4.3.5.2. Growth Prospects
      • 7.4.3.6. Others
        • 7.4.3.6.1. Market Opportunities and Trends
        • 7.4.3.6.2. Growth Prospects
  • 7.5. Middle East and Africa
    • 7.5.1. By Product Type
    • 7.5.2. By Application
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
        • 7.5.3.1.1. Market Opportunities and Trends
        • 7.5.3.1.2. Growth Prospects
      • 7.5.3.2. UAE
        • 7.5.3.2.1. Market Opportunities and Trends
        • 7.5.3.2.2. Growth Prospects
      • 7.5.3.3. South Africa
        • 7.5.3.3.1. Market Opportunities and Trends
        • 7.5.3.3.2. Growth Prospects
  • 7.6. Asia Pacific
    • 7.6.1. By Product Type
    • 7.6.2. By Application
    • 7.6.3. By Country
      • 7.6.3.1. China
        • 7.6.3.1.1. Market Opportunities and Trends
        • 7.6.3.1.2. Growth Prospects
      • 7.6.3.2. Japan
        • 7.6.3.2.1. Market Opportunities and Trends
        • 7.6.3.2.2. Growth Prospects
      • 7.6.3.3. India
        • 7.6.3.3.1. Market Opportunities and Trends
        • 7.6.3.3.2. Growth Prospects
      • 7.6.3.4. Indonesia
        • 7.6.3.4.1. Market Opportunities and Trends
        • 7.6.3.4.2. Growth Prospects
      • 7.6.3.5. South Korea
        • 7.6.3.5.1. Market Opportunities and Trends
        • 7.6.3.5.2. Growth Prospects
      • 7.6.3.6. Taiwan
        • 7.6.3.6.1. Market Opportunities and Trends
        • 7.6.3.6.2. Growth Prospects
      • 7.6.3.7. Thailand
        • 7.6.3.7.1. Market Opportunities and Trends
        • 7.6.3.7.2. Growth Prospects
      • 7.6.3.8. Others
        • 7.6.3.8.1. Market Opportunities and Trends
        • 7.6.3.8.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Hoffmann-La Roche AG
  • 9.2. Amgen Inc.
  • 9.3. AbbVie Inc.
  • 9.4. Novo Nordisk A/S
  • 9.5. Johnson & Johnson
  • 9.6. Takeda Pharmaceutical Company
  • 9.7. Alexion Pharmaceuticals
  • 9.8. Samsung Biologics
  • 9.9. UCB S.A.
  • 9.10. Merck & Co. Inc
  • 9.11. Eli Lilly and Company
  • 9.12. Sanofi SA